Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Michael Dempsey, Michelle Mocarski, Jakob Langer & Barnaby Hunt. (2018) Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of Medical Economics 21:11, pages 1110-1118.
Read now
Read now
Articles from other publishers (16)
Rachel M. A. Linger, Joseph O. Fadare, Ye Shen & Lon J. Van Winkle. (2023) Editorial: Emerging talents in pharmacology: Drugs outcomes research and policies 2022. Frontiers in Pharmacology 14.
Crossref
Crossref
Guangxin Han, Shanshan Hu, Xiaoning Zhang, Zhikun Qiu & Zhe Huang. (2022) Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China. Frontiers in Pharmacology 13.
Crossref
Crossref
Giuseppe Lisco, Anna De Tullio, Edoardo Guastamacchia & Vincenzo Triggiani. (2021) Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature. Endocrine, Metabolic & Immune Disorders - Drug Targets 21:4, pages 626-646.
Crossref
Crossref
Francisco J. Barrera, Freddy JK. Toloza, Oscar J. Ponce, Jorge A. Zuñiga-Hernandez, Larry J. Prokop, Nilay D. Shah, Gordon Guyatt, Rene Rodriguez-Gutierrez & Victor M. Montori. (2020) The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes. Endocrine 71:1, pages 47-58.
Crossref
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nathorn Chaiyakunapruk, Mark McEvoy, John Attia & Ammarin Thakkinstian. (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Research & Care 8:1, pages e001020.
Crossref
Crossref
Ping Wu, Zhenyu Liu, Xiaohong Jiang & Hao Fang. (2020) An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes. Current Drug Targets 21:5, pages 445-457.
Crossref
Crossref
Anthony J. CannonAlexandra BargiotaLiana BillingsBarnaby HuntLawrence A. LeiterSamuel MalkinMichelle Mocarski, Mattis Flyvholm RantheAlisa Schiffman & Ankur Doshi. (2020) Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. Journal of Managed Care & Specialty Pharmacy 26:2, pages 143-153.
Crossref
Crossref
Mark Warren & Donna Steel. (2020) Clinical Use of IDegLira: Initiation to Titration After Basal Insulin. Clinical Diabetes 38:1, pages 62-70.
Crossref
Crossref
Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt & Samuel Joseph Paul Malkin. (2019) Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Therapy 10:4, pages 1297-1317.
Crossref
Crossref
Pedro Mezquita Raya, Francisco Javier Ampudia Blasco, Barnaby Hunt, Virginia Martin, Brian Larsen Thorsted, Amaury Basse & Hermione Price. (2019) Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence. Diabetes, Obesity and Metabolism 21:6, pages 1349-1356.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
Néboa Zozaya, Margarita Capel, Susana Simón & Alfonso Soto-González. (2019) A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031987657.
Crossref
Crossref
Russell Drummond, Samuel Malkin, Michelle Du Preez, Xin Ying Lee & Barnaby Hunt. (2018) The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, Obesity and Metabolism 20:10, pages 2371-2378.
Crossref
Crossref
Satish K. GargAmanda H. RewersH. Kaan Akturk. (2018) New Medications for the Treatment of Diabetes. Diabetes Technology & Therapeutics 20:S1, pages S-139-S-153.
Crossref
Crossref
Amy Putiri, Jacqueline Close, Harold Lilly, Nathalie Guillaume & Guan-Cheng Sun. (2017) Qigong Exercises for the Management of Type 2 Diabetes Mellitus. Medicines 4:3, pages 59.
Crossref
Crossref
Barnaby Hunt, Michelle Mocarski, William J. Valentine & Jakob Langer. (2017) IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Therapy 8:3, pages 531-544.
Crossref
Crossref